Description: A listing of articles on managed care and health care issues.

Description: Health Watch, Issue 79, December 2015, Health Watch

Description: Discover the key components of value-based care (VBC) contracts and their impact on provider credibility. Learn about benchmarks, measurement period results, and the unique challenges providers face in managing insurance risk. Gain insights into reducing costs and aligning financial incentives in the US healthcare market.

Description: Recap of the Health Policy Summit held in honor of Health Affairs’ 25th anniversary.

Description: Update on the SOA Health Section's Public Health Task Force's comment on Health People 2030.

Description: The article provides insights about the need for revolutionary actuaries in Saudi Arabia due to the reform that is happening across the kingdom under all sectors. Then I talk briefly about the health sector and the transformation that is happing in the sector, and how qualified health actuaries can contribute to this health reform.

Description: This article is the third in a series from the '2011 Living To 100 Symposium.' It examines the growing concern about doctor to patient ratio, including perspectives from Canada, the U.S. and the U.K.

Description: Article summarizes the sessions of the 2011 SOA Health Meeting held in Boston.

Description: This article examines the dynamic environment of the health care system in the United States and the challenges facing the health actuary.

Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.